文献速递儿童呼吸儿童感染

β-内酰胺单药与联合大环内酯类治疗住院儿童肺炎的效果比较

Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
PubMed 文献 · JAMA Pediatr · 2017-01-01

一项基于美国三个儿童医院的多中心前瞻性队列研究,纳入1418例影像学确诊的住院肺炎患儿,比较β-内酰胺单药与β-内酰胺联合大环内酯类的疗效。结果显示两组住院时长无显著差异(中位55 vs 59小时;调整后HR 0.87,95%CI 0.74-1.01),次要结局亦无显著差异。结论提示经验性联合大环内酯类治疗无额外获益。

要点

  • β-内酰胺单药与联合大环内酯类在住院肺炎患儿中住院时长无显著差异。
  • 倾向性匹配队列及次要结局(ICU入住、再住院、恢复)均无显著差异。
  • 结果对常规经验性联合大环内酯类治疗的必要性提出疑问。

核心结论

  • 对于住院的社区获得性肺炎患儿,经验性β-内酰胺联合大环内酯类治疗相比β-内酰胺单药治疗无额外获益。

研究设计与样本

  • 研究分析Etiology of Pneumonia in the Community Study的数据,该研究为多中心、前瞻性、基于人群的社区获得性肺炎住院研究,于2010年1月1日至2012年6月30日在田纳西州纳什维尔、孟菲斯和犹他州盐湖城的3家儿童医院开展。
  • 纳入所有18岁及以下、影像学确诊肺炎且接受β-内酰胺单药或β-内酰胺联合大环内酯类治疗的住院患儿。
  • 采用多变量Cox比例风险回归模型分析治疗组与住院时长的关联,并在倾向性匹配队列中进一步评估。

主要发现

  • 研究共纳入1418例患儿(女693例,男725例),中位年龄27个月(四分位距12-69个月)。
  • 1019例(71.9%)接受β-内酰胺单药治疗,399例(28.1%)接受β-内酰胺联合大环内酯类治疗。
  • 非匹配队列中,两组住院时长无统计学显著差异(中位55 vs 59小时;调整后风险比0.87;95%CI 0.74-1.01)。
  • 倾向性匹配队列(n=560,39.5%)结果相似。
  • 次要结局(包括入住ICU、再住院和随访时自报恢复)在治疗组间无显著差异。

临床怎么用

  • 对于住院的社区获得性肺炎患儿,经验性联合大环内酯类治疗不应作为常规,需权衡利弊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: β-Lactam monotherapy and β-lactam plus macrolide combination therapy are both common empirical treatment strategies for children hospitalized with pneumonia, but few studies have evaluated the effectiveness of these 2 treatment approaches. OBJECTIVE: To compare the effectiveness of β-lactam monotherapy vs β-lactam plus macrolide combination therapy among a cohort of children hospitalized with pneumonia. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from the Etiology of Pneumonia in the Community Study, a multicenter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted from January 1, 2010, to June 30, 2012, in 3 children's hospitals in Nashville, Tennessee; Memphis, Tennessee; and Salt Lake City, Utah. The study included all children (up to 18 years of age) who were hospitalized with radiographically confirmed pneumonia and who received β-lactam monotherapy or β-lactam plus macrolide combination therapy. Data analysis was completed in April 2017. MAIN OUTCOMES AND MEASURES: We defined the referent as β-lactam monotherapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate. Use of a β-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group. We modeled the association between these groups and patients' length of stay using multivariable Cox proportional hazards regression. Covariates included demographic, clinical, and radiographic variables. We further evaluated length of stay in a cohort matched by propensity to receive combination therapy. Logistic regression was used to evaluate secondary outcomes in the unmatched cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow-up. RESULTS: Our study included 1418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 months). This cohort was 60.1% of the 2358 children enrolled in the Etiology of Pneumonia in the Community Study with radiographically confirmed pneumonia in the study period; 1019 (71.9%) received β-lactam monotherapy and 399 (28.1%) received β-lactam plus macrolide combination therapy. In the unmatched cohort, there was no statistically significant difference in length of hospital stay between children receiving β-lactam monotherapy and combination therapy (median, 55 vs 59 hours; adjusted hazard ratio, 0.87; 95% CI, 0.74-1.01). The propensity-matched cohort (n = 560, 39.5%) showed similar results. There were also no significant differences between treatment groups for the secondary outcomes. CONCLUSIONS AND RELEVANCE: Empirical macrolide combination therapy conferred no benefit over β-lactam monotherapy for children hospitalized with community-acquired pneumonia. The results of this study elicit questions about the routine empirical use of macrolide combination therapy in this population.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Williams DJ, Edwards KM, Self WH, et al. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia. JAMA Pediatr. 2017. PMID: 29084336. doi:10.1001/jamapediatrics.2017.3225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。